Danish medical product manufacturers Coloplast has experienced an 8% rise in sales in the first three quarters of 2011/12, amounting to DKK 8.174 billion. The EBIT-Margin also improved by 5% to 29%.
A number of sectors of the business contributed to this sales growth: ostomy care (up 6%), continence care (up 9%) and urology (up 5%). The wound care and skin care sector saw a decline of 2%.
For the full year, Coloplast expects to maintain the positive organic sales growth of the year so far, at around 6%. In the next 3-5 years, the company wants to consolidate its position as market leader in Europe, drive growth in the key markets outside Europe (USA, Japan, Australia) and also expand into new markets, including China.
[ilink url=“http://www.coloplast.com/about/news/2012-q3-press-release“] Link zur Quelle (Coloplast)[/ilink]